Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
4
×
life sciences
national blog main
national top stories
biotech
boston
san francisco blog main
clinical trials
deals
gene therapy
new york blog main
san diego blog main
san francisco top stories
startups
third rock ventures
vc
acetylon pharmaceuticals
ally bridge group
ambys medicines
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
big data analytics
blackrock
bluebird bio
casdin capital
cell therapy
constellation pharmaceuticals
crispr
david walt
diabetic nephropathy
diagnostics
duchenne muscular dystrophy
dyne therapeutics
eventide asset management
facioscapulohumeral muscular dystrophy
feng zhang
focal segmental glomerulosclerosis
What
diseases
4
×
medicines
4
×
bio
biotech
drug
genetic
ipo
new
ago
aiming
ambys
analysis
big
biotechs
bring
company
considering
control
create
crispr
data
deadly
deal
debuted
develop
diagnostic
dyne
early
editing
employing
expected
experimental
eyes
fix
formed
future
gene
goldfinch
having
heats
Language
unset
Current search:
medicines
×
diseases
×
" boston top stories "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
